溃疡性结肠炎治疗中的临床药代动力学与药效学考量
本文综述了溃疡性结肠炎(UC)治疗中药物的药代动力学与药效学特点。按升阶梯策略,5-氨基水杨酸、皮质类固醇、硫嘌呤、钙调神经磷酸酶抑制剂和单克隆抗体依次用于不同严重程度患者。硫嘌呤活性代谢物6-TGN的TDM有益,TPMT基因分型临床价值未明;抗TNF药物药代动力学受体重、白蛋白和抗药抗体影响,TDM对原发无应答和继发失应答者可能有益。
要点
- 硫嘌呤活性代谢物6-TGN的治疗药物监测已被证明有益。
- 抗TNF药物药代动力学受体重、白蛋白状态和抗药抗体影响。
- 联用免疫调节剂可降低抗TNF药物免疫原性,某些患者可能优于单药治疗。
核心结论
- UC治疗需根据疾病严重程度、病变部位和用药史选择药物,并考虑药代动力学与药效学特点。
- 硫嘌呤的TDM(6-TGN)已证明有益,但TPMT基因分型的临床获益和相关性尚未明确。
- 抗TNF药物TDM对原发无应答和继发失应答患者可能有益,维多珠单抗TDM的潜在获益尚待确定。
研究设计与样本
- 本文为综述,总结UC治疗中药物的临床药代动力学与药效学考量。
主要发现
- 5-氨基水杨酸是轻中度活动性UC升阶梯治疗的第一步。
- 皮质类固醇仅用于中重度活动性UC的缓解诱导,因长期使用有副作用。
- 硫嘌呤单药诱导治疗因起效慢而不优选。
- 钙调神经磷酸酶抑制剂(环孢素A、他克莫司)起效较快,可用于激素难治性重度活动性UC。
- 抗TNF药物药代动力学变异性与体重、白蛋白状态和抗药抗体相关。
关键数值与推荐
- 硫嘌呤TDM监测6-TGN已被证明有益。
- TPMT存在遗传多态性,但基因分型的临床获益和相关性尚未明确建立。
- 联用免疫调节剂(硫嘌呤/甲氨蝶呤)可降低免疫原性,某些患者中抗TNF联合免疫调节剂可能优于单药治疗。
- 抗TNF药物TDM对原发无应答和继发失应答患者可能有益。
- 维多珠单抗治疗中应用TDM的潜在获益尚待确定。
临床怎么用
- 轻中度活动性UC可首选5-氨基水杨酸。
- 中重度活动性UC可用皮质类固醇诱导缓解,避免长期使用。
- 硫嘌呤治疗时可监测6-TGN以优化疗效。
- 抗TNF治疗原发无应答或继发失应答时可考虑TDM。
- 特定患者抗TNF联合免疫调节剂可降低免疫原性。
局限性
- TPMT基因分型的临床获益和相关性尚未明确建立。
- 维多珠单抗TDM的潜在获益尚待确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology, probably caused by a combination of genetic and environmental factors. The treatment of patients with active UC depends on the severity, localization and history of IBD medication. According to the classic step-up approach, treatment with 5-aminosalicylic acid compounds is the first step in the treatment of mild to moderately active UC. Corticosteroids, such as prednisolone are used in UC patients with moderate to severe disease activity, but only for remission induction therapy because of side effects associated with long-term use. Thiopurines are the next step in the treatment of active UC but monotherapy during induction therapy in UC patients is not preferred because of their slow onset. Therapeutic drug monitoring (TDM) of the pharmacologically active metabolites of thiopurines, 6-thioguanine nucleotide (6-TGN), has proven to be beneficial. Thiopurine S-methyltransferase (TMPT) plays a role in the metabolic conversion pathway of thiopurines and exhibits genetic polymorphism; however, the clinical benefit and relevance of TPMT genotyping is not well established. In patients with severely active UC refractory to corticosteroids, calcineurin inhibitors such as ciclosporin A (CsA) and tacrolimus are potential therapeutic options. These agents usually have a rather rapid onset of action. Monoclonal antibodies (anti-tumor necrosis factor [TNF] agents, vedolizumab) are the last pharmacotherapeutic option for UC patients before surgery becomes inevitable. Body weight, albumin status and antidrug antibodies contribute to the variability in the pharmacokinetics of anti-TNF agents. Additionally, the use of concomitant immunomodulators (thiopurines/methotrexate) lowers the rate of immunogenicity, and therefore the concomitant use of anti-TNF therapy with an immunomodulator may confer some advantage compared with monotherapy in certain patients. TDM of anti-TNF agents could be beneficial in patients with primary nonresponse and secondary loss of response. The potential benefit of applying TDM during vedolizumab treatment has yet to be determined.
引用
- Berends SE, Strik AS, Löwenberg M, et al. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet. 2019. PMID: 29752633. doi:10.1007/s40262-018-0676-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。